Privia Health Group, Inc. PRVA
24.37 USD -0.17 (-0.69%)
At closeNov 10, 2026, 4:00 PM EST
24.37 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
23.67 Day range 24.78
18.92 52-week range 28.82
- YTD
- +2.78%
- 1 year
- +4.10%
News
zacks.com 3 Reasons Why Growth Investors Shouldn't Overlook Privia Health (PRVA) Privia Health (PRVA) could produce exceptional returns because of its solid growth attributes.
zacks.com How Much Upside is Left in Privia Health (PRVA)? Wall Street Analysts Think 29.22% The average of price targets set by Wall Street analysts indicates a potential upside of 29.2% in Privia Health (PRVA). While the effectiveness of this highly sought-after metric is questionable, the…
benzinga.com Canaccord Genuity Maintains Buy on Privia Health Gr, Raises Price Target to $33 Canaccord Genuity analyst Richard Close maintains Privia Health Gr (NASDAQ:PRVA) with a Buy and raises the price target from $32 to $33.
benzinga.com Piper Sandler Maintains Overweight on Privia Health Gr, Raises Price Target to $38 Piper Sandler analyst Jessica Tassan maintains Privia Health Gr (NASDAQ:PRVA) with a Overweight and raises the price target from $36 to $38.
zacks.com Privia Health (PRVA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Privia Health (PRVA) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall…
benzinga.com Privia Health Gr Q3 2026 Earnings Call Transcript Privia Health Gr (NASDAQ:PRVA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
zacks.com Privia Health (PRVA) Q3 Earnings and Revenues Top Estimates Privia Health (PRVA) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.05 per share a year ago.
benzinga.com Privia Health Gr Raises FY2026 Sales Guidance from $2.350B-$2.450B to $2.500B-$2.550B vs $2.457B Est Privia Health Gr (NASDAQ:PRVA) raises FY2026 sales outlook from $2.350 billion-$2.450 billion to $2.500 billion-$2.550 billion vs $2.457 billion estimate.
globenewswire.com Privia Health Reports Strong Third Quarter and Year-to-Date 2026 Results Privia Health Reports Strong Q3 and YTD 2026 Results - Adjusted EBITDA of $114.7M, +21.9% from YTD'25 – FY'26 Guidance Raised for All Key Financial Metrics
benzinga.com Privia Health Group Acquires American Choice Healthcare MSSP For ~$36M Privia Health Group, Inc. (Nasdaq: PRVA) announced the acquisition of American Choice Healthcare MSSP, LLC (ACH), a wholly-owned subsidiary of Cano Health. The Accountable Care Organization (ACO)…
benzinga.com Full Transcript: Privia Health Gr Q2 2026 Earnings Call Privia Health Gr (NASDAQ:PRVA) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to…
benzinga.com CORRECTION: Privia Health Gr Q2 Adj. EPS $0.19 Beats $0.07 Estimate, Sales $632.600M Beat $599.186M Estimate Privia Health Gr (NASDAQ:PRVA) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.07 by 171.43 percent. This is a 11.76 percent increase over earnings of…- benzinga.com Privia Health Gr Affirms FY2026 Sales Guidance of $2.350B-$2.450B vs $2.422B Est Privia Health Gr (NASDAQ:PRVA) affirms FY2026 sales outlook from $2.350 billion-$2.450 billion to $2.350 billion-$2.450 billion vs $2.422 billion estimate.
benzinga.com Top 3 Health Care Stocks That May Implode This Month Warning: RSI is above 70 for 3 overbought stocks in healthcare. Progyny, 10X Genomics, and Privia Health have high RSI values and strong price action.
benzinga.com Canaccord Genuity Maintains Buy on Privia Health Gr, Lowers Price Target to $34 Canaccord Genuity analyst Richard Close maintains Privia Health Gr (NASDAQ:PRVA) with a Buy and lowers the price target from $35 to $34.- benzinga.com Privia Health Gr Affirms FY2026 Sales Guidance of $2.350B-$2.450B vs $2.469B Est Privia Health Gr (NASDAQ:PRVA) affirms FY2026 sales outlook from $2.350 billion-$2.450 billion to $2.350 billion-$2.450 billion vs $2.469 billion estimate.
benzinga.com Privia Health Gr Q1 Adj. EPS $0.19 Beats $0.07 Estimate, Sales $603.800M Beat $580.654M Estimate Privia Health Gr (NASDAQ:PRVA) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.07 by 137.5 percent. This is a 18.75 percent increase over earnings of…- benzinga.com Evercore ISI Group Maintains Outperform on Privia Health Gr, Lowers Price Target to $26 Evercore ISI Group analyst Elizabeth Anderson maintains Privia Health Gr (NASDAQ:PRVA) with a Outperform and lowers the price target from $30 to $26.
- benzinga.com Barclays Maintains Equal-Weight on Privia Health Gr, Raises Price Target to $25 Barclays analyst Andrew Mok maintains Privia Health Gr (NASDAQ:PRVA) with a Equal-Weight and raises the price target from $23 to $25.
benzinga.com Breaking Down Privia Health Gr: 5 Analysts Share Their Views - benzinga.com Citigroup Maintains Buy on Privia Health Gr, Lowers Price Target to $32 Citigroup analyst Daniel Grosslight maintains Privia Health Gr (NASDAQ:PRVA) with a Buy and lowers the price target from $34 to $32.
- benzinga.com Amalgam Announces Privia Health-Led Colorectal Cancer Screening Program Demonstrates 84% Screening Rates In 2024, Surpassing 80% Goal Amalgam Rx, Inc., a leader in data-driven, AI-powered healthcare engagement and clinical decision support, today announced results from a Privia Health (NASDAQ: PRVA)-led colorectal cancer (CRC)…
- benzinga.com Truist Securities Maintains Buy on Privia Health Gr, Raises Price Target to $33 Truist Securities analyst Jailendra Singh maintains Privia Health Gr (NASDAQ:PRVA) with a Buy and raises the price target from $31 to $33.
- benzinga.com Canaccord Genuity Maintains Buy on Privia Health Gr, Raises Price Target to $35 Canaccord Genuity analyst Richard Close maintains Privia Health Gr (NASDAQ:PRVA) with a Buy and raises the price target from $34 to $35.
benzinga.com Earnings Scheduled For February 26, 2026 
benzinga.com Privia Health Gr Earnings Report: Q4 Overview 
benzinga.com Privia Health Gr Sees FY2026 Sales $2.350B-$2.450B vs $2.380B Est Privia Health Gr (NASDAQ:PRVA) sees FY2026 sales of $2.350 billion-$2.450 billion vs $2.380 billion analyst estimate.- benzinga.com Privia Health Gr Q4 Adj. EPS $0.25 Beats $0.04 Estimate, Sales $541.200M Miss $565.535M Estimate Privia Health Gr (NASDAQ:PRVA) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.04 by 614.29 percent. This is a 19.05 percent increase over earnings of…
benzinga.com Renaissance Loads Up on Netflix, Lam Research, ServiceNow — Smart Money Signals Shift Renaissance Group made massive moves in Netflix, Lam Research and ServiceNow, signaling rising hedge fund conviction in streaming, AI chips and enterprise cloud.- benzinga.com Stephens & Co. Reiterates Overweight on Privia Health Gr, Maintains $32 Price Target Stephens & Co. analyst Jeff Garro reiterates Privia Health Gr (NASDAQ:PRVA) with a Overweight and maintains $32 price target.
- benzinga.com JP Morgan Maintains Overweight on Privia Health Gr, Raises Price Target to $33 JP Morgan analyst Lisa Gill maintains Privia Health Gr (NASDAQ:PRVA) with a Overweight and raises the price target from $32 to $33.
- benzinga.com BMO Capital Initiates Coverage On Privia Health Gr with Outperform Rating, Announces Price Target of $30 BMO Capital analyst Sean Dodge initiates coverage on Privia Health Gr (NASDAQ:PRVA) with a Outperform rating and announces Price Target of $30.
- benzinga.com Canaccord Genuity Maintains Buy on Privia Health Gr, Raises Price Target to $34 Canaccord Genuity analyst Richard Close maintains Privia Health Gr (NASDAQ:PRVA) with a Buy and raises the price target from $32 to $34.
benzinga.com Barclays Maintains Equal-Weight on Privia Health Gr, Raises Price Target to $23 Barclays analyst Andrew Mok maintains Privia Health Gr (NASDAQ:PRVA) with a Equal-Weight and raises the price target from $22 to $23.- benzinga.com Truist Securities Reiterates Buy on Privia Health Gr, Raises Price Target to $31 Truist Securities analyst Jailendra Singh reiterates Privia Health Gr (NASDAQ:PRVA) with a Buy and raises the price target from $30 to $31.
- benzinga.com Evercore ISI Group Maintains Outperform on Privia Health Gr, Raises Price Target to $30 Evercore ISI Group analyst Elizabeth Anderson maintains Privia Health Gr (NASDAQ:PRVA) with a Outperform and raises the price target from $28 to $30.
- benzinga.com Citizens Maintains Market Outperform on Privia Health Gr, Raises Price Target to $31 Citizens analyst Constantine Davides maintains Privia Health Gr (NASDAQ:PRVA) with a Market Outperform and raises the price target from $30 to $31.
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com Privia Health Gr Raises FY2025 Sales Guidance from $1.800B-$1.900B to $2.050B-$2.100B vs $3.359B Est Privia Health Gr (NASDAQ:PRVA) raises FY2025 sales outlook from $1.800 billion-$1.900 billion to $2.050 billion-$2.100 billion vs $3.359 billion estimate.
- benzinga.com Privia Health Gr Q3 Adj. EPS $0.29 Beats $0.05 Estimate, Sales $580.400M Miss $781.946M Estimate Privia Health Gr (NASDAQ:PRVA) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $0.05 by 437.04 percent. This is a 45 percent increase over earnings of…
- benzinga.com Barclays Maintains Equal-Weight on Privia Health Gr, Raises Price Target to $22 Barclays analyst Andrew Mok maintains Privia Health Gr (NASDAQ:PRVA) with a Equal-Weight and raises the price target from $21 to $22.
benzinga.com Privia Health Acquires Evolent's ACO Business To Boost Value-Based Care Privia Health (PRVA) to acquire Evolent Health's (EVH) ACO business for $100M, expanding its value-based care footprint.- benzinga.com What 5 Analyst Ratings Have To Say About Privia Health Gr
- benzinga.com Stephens & Co. Reiterates Overweight on Privia Health Gr, Maintains $32 Price Target Stephens & Co. analyst Jeff Garro reiterates Privia Health Gr (NASDAQ:PRVA) with a Overweight and maintains $32 price target.
- benzinga.com Breaking Down Privia Health Gr: 4 Analysts Share Their Views
- benzinga.com Stephens & Co. Reiterates Overweight on Privia Health Gr, Maintains $32 Price Target Stephens & Co. analyst Jeff Garro reiterates Privia Health Gr (NASDAQ:PRVA) with a Overweight and maintains $32 price target.
- benzinga.com JMP Securities Maintains Market Outperform on Privia Health Gr, Raises Price Target to $30 JMP Securities analyst David M. Scharf maintains Privia Health Gr (NASDAQ:PRVA) with a Market Outperform and raises the price target from $29 to $30.
- benzinga.com Beyond The Numbers: 4 Analysts Discuss Privia Health Gr Stock
- benzinga.com Piper Sandler Maintains Overweight on Privia Health Gr, Lowers Price Target to $35 Piper Sandler analyst Sean Wieland maintains Privia Health Gr (NASDAQ:PRVA) with a Overweight and lowers the price target from $36 to $35.
- benzinga.com Privia Health Gr Affirms FY2025 Sales Guidance of $1.800B-$1.900B vs $3.242B Est Privia Health Gr (NASDAQ:PRVA) affirms FY2025 sales outlook from $1.800 billion-$1.900 billion to $1.800 billion-$1.900 billion vs $3.242 billion estimate.